CA 19-9 is a marker for which of the following:September 2011
The question asks which cancer CA 19-9 is a marker for. I remember that CA 19-9 is commonly linked to pancreatic cancer. But wait, are there other cancers it might be associated with? Maybe colorectal or biliary tract cancers? I should confirm that. Let me think. Yes, CA 19-9 is elevated in about 80% of pancreatic adenocarcinomas. It's not specific to pancreatic cancer alone, but it's the most common one. Other options might include lung, breast, or ovarian cancers, but their markers are different. For example, CA 125 for ovarian, CEA for colorectal, and PSA for prostate. So the correct answer here is pancreatic cancer.
Now, the wrong options. Let's say the options were pancreatic, lung, breast, and ovarian. Then options B, C, and D would be incorrect. Each of these has different markers. I need to make sure to explain why each is wrong. For example, CA 15-3 or CA 27.29 for breast, CEA for colorectal, and CA 125 for ovarian. Also, CA 19-9 isn't specific to one cancer, but pancreatic is the primary one.
Clinical pearl: Remember that CA 19-9 is a glycoprotein antigen, and it's used mainly for monitoring treatment response and recurrence in pancreatic cancer patients. High levels don't always mean cancer, as some benign conditions like pancreatitis can also elevate it. But the key point is its association with pancreatic cancer.
Putting it all together, the explanation should start with the core concept, then explain why pancreatic is correct, address each wrong option, and end with a clinical tip. Need to keep it concise but thorough, within the character limit. Also, make sure the sections are labeled correctly without markdown headings, just bold text. Avoid any markdown except bold and line breaks. Let me check the structure again to ensure all sections are included and the correct answer is clearly stated.
**Core Concept**
CA 19-9 is a tumor-associated glycoprotein antigen primarily elevated in **pancreatic adenocarcinoma**. It is used for monitoring treatment response and recurrence in pancreatic cancer patients, though it lacks absolute specificity due to elevation in benign biliary and pancreatic conditions.
**Why the Correct Answer is Right**
CA 19-9 (carbohydrate antigen 19-9) is a sialylated Lewis blood group antigen expressed on the surface of gastrointestinal and biliary epithelial cells. **Pancreatic adenocarcinoma** is the most common malignancy associated with CA 19-9 elevation, with ~80% of patients showing significantly increased levels. Its production correlates with tumor burden but is not diagnostic alone due to overlapping elevations in cholangiocarcinoma, gallbladder cancer, and benign diseases like pancreatitis or cholestasis.
**Why Each Wrong Option is Incorrect**